



## Rx FOR SUCCESS

## Scleroderma/CREST

**Diffuse scleroderma**, also called progressive systemic sclerosis (PSS), is a generalized disorder of connective tissue characterized by inflammation and scarring of the skin, esophagus, intestinal tract, heart, lungs, and kidneys. Primary biliary cirrhosis can occur. The leading cause of death is renal failure. The cause is obscure. Raynaud's phenomenon occurs in 95% of PSS and can precede other symptoms by years. The course of scleroderma is unpredictable and variable in severity. In disease limited to mild skin involvement, scleroderma is only slowly progressive, and affected individuals may live a normal life span. The prognosis for scleroderma is poorer when cardiac, pulmonary, or renal manifestations are present. The course of the disease may take many years, but some experience a rapid progression to death. Treatment of scleroderma depends on the locale, extent, and severity of the disease and includes aspirin, other non-steroidal anti-inflammatory agents, steroids, and penicillamine.

**CREST** syndrome is scleroderma characterized by:

- C:** Calcinosis cutis (calcium formation in the tips of the fingers or toes)
- R:** Raynaud's phenomenon (cold-induced blanching of the fingers or toes followed by blue color, then redness)
- E:** Esophageal mobility problems that interfere with swallowing
- S:** Sclerodactyly (thickening of the skin on the fingers)
- T:** Telangiectasis (small vessels are seen on the skin)

**Limited scleroderma** involves the skin exclusively and is characterized by skin that appears tightly drawn, bound, and fixed to underlying structures, especially in the fingers where contractures may occur. The skin on the face may be involved in limited scleroderma. Ulcers may develop over bony prominences and on the finger tips.

**Morphea** is a localized form of systemic scleroderma that is characterized by the formation of white or pink patches, bands, or lines that are firm. Other manifestations of this disease rarely occur.

This material is designed to provide general information about the subject matter covered. It should be used with the understanding that we are not rendering legal, accounting, or tax advice. Such services should be provided by the client's own professional advisors. Accordingly, any information in this document cannot be used by any taxpayer for purposes of avoiding penalties under the Internal Revenue Code.

This material is intended for insurance informational purposes only and is not personal medical advice for clients. Rates and availability will vary based on the satisfaction of our underwriting criteria. Underwriting rules are subject to change at our discretion. This marketing material is subject to an expiration date, and use of this material must be discontinued as of the expiration date.

Insurance issued by The Prudential Insurance Company of America and its affiliates, Newark, NJ.

**NOT FOR CONSUMER USE.**

© 2013 Prudential Financial, Inc. and its related entities.  
0192225-00002-00 Ed. 01/2013 Exp. 01/15/2015 Rx 068

**Securities and Insurance Products:**

Not Insured by FDIC or Any Federal Government Agency.  
May Lose Value.

Not a Deposit of or Guaranteed by Any Bank or Bank Affiliate.



**Prudential**  
Bring Your Challenges<sup>®</sup>

## UNDERWRITING CONSIDERATIONS FOR SCLERODERMA/CREST

▶ Progressive systemic sclerosis	Usually a decline
▶ Limited scleroderma/CREST	
▶ Within 1 year of diagnosis	Decline
▶ 1 to 5 years of diagnosis	Table D
▶ After 5 years	Table C
▶ Involvement beyond CREST	Decline
▶ Localized scleroderma—morphea or linea	0

Minor credits may be given in the over-65 age group or if there is no disease activity for 5 years.

*To get an idea of how a client with Scleroderma/CREST would be viewed in the underwriting process, use the Ask “Rx”pert Underwriter on the next page for an informal quote.*

### Ask “Rx”pert Underwriter (Ask Our Expert)

After reading the *Rx for Success* on Scleroderma/CREST, use this form to Ask “Rx”pert Underwriter for an informal quote.

Producer \_\_\_\_\_ Phone \_\_\_\_\_ Fax \_\_\_\_\_  
 Client \_\_\_\_\_ Age/DOB \_\_\_\_\_ Sex \_\_\_\_\_

If your client has a history of Scleroderma/CREST, please answer the following.

#### 1. Please note type of scleroderma.

- Localized scleroderma—morphea or linea  
 Limited scleroderma/CREST  
 Progressive systemic sclerosis—diffuse scleroderma

#### 2. Please list date of first diagnosis.

\_\_\_\_\_

#### 3. Is your client on any medications?

- Yes. Please give details. \_\_\_\_\_  
 No

#### 4. Please check if your client has had any of the following.

- |  |   |
|--|---|
| <input type="checkbox"/> Weight loss       | <input type="checkbox"/> Biliary cirrhosis        |
| <input type="checkbox"/> Heart disease     | <input type="checkbox"/> Liver enzyme abnormality |
| <input type="checkbox"/> Lung disease      | <input type="checkbox"/> Kidney disease           |
| <input type="checkbox"/> Raynaud’s disease | <input type="checkbox"/> Trouble swallowing       |

#### 5. Have all polyps been removed?

- Yes. Please give most recent test results. \_\_\_\_\_  
 No

#### 6. Please note date of last follow-up colonoscopy.

\_\_\_\_\_

#### 7. Has your client smoked cigarettes in the last 12 months?

- Yes. Please give details. \_\_\_\_\_  
 No

#### 8. Does your client have any other major health problems (e.g., cancer, etc.)?

- Yes. Please give details. \_\_\_\_\_  
 No